Summary:
Phase 1, non-randomized, open-label study to assess the pharmacokinetics, safety and tolerability of pf-07321332 boosted with ritonavir in adult participants with moderate hepatic impairment and healthy participants with normal hepatic function
Qualified Participants Must:
• Male or Female age 18 to 75 years old
• Have a BMI of 17.5 to 40 (must weight at least 110)
• Must have liver damage, liver issue or liver disease
Qualified Participants May Receive:
Compensation up to $1600.00